Table 6 RET gene fusions inhibitors in clinical trials [40]

NCT01639508

Cabozantinib

Phase II

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

NCT04194944

Selpercatinib vs Carboplatin/Cisplatin + Pemetrexed ± Pembrolizumab

Phase III

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)

NCT04268550

Selpercatinib

Phase II

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04131543

Cabozantinib

Phase II

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

NCT03037385

Pralsetinib (BLU-667)

Phase I/II

Phase I/II Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

NCT04222972

Pralsetinib vs Carboplatin/Cisplatin + Pemetrexed ± Pembrolizumab or Carboplatin/Cisplatin Gemcitabine (Squamous histology)

Phase III

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC

NCT04683250

TAS0953/HM06

Phase I/II

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))

NCT03780517

BOS172738

Phase I

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

NCT03157128

LOXO-292 (Selpercatinib)

Phase I/II

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT04161391

TPX-0046

Phase I/II

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations